UroGen Pharma (URGN) is a clinical-stage biotechnology company focused on urothelial and specialty cancers via its proprietary RTGel sustained-release hydrogel technology, showing robust recent commercial momentum from approved products Jelmyto and Zusduri (strong Q2 2026 revenue growth), multiple analyst Buy ratings with raised price targets, an advancing pipeline, and stock outperformance versus the S&P 500 over recent periods, though it remains unprofitable with ongoing clinical and competitive risks.
Fact: UroGen Pharma Ltd. was incorporated in 2004 (originally with operations in Israel) and is headquartered in Princeton, New Jersey. It develops and commercializes solutions for urothelial and specialty cancers using its RTGel reverse-thermal hydrogel platform technology for sustained drug release in the urinary tract.
Fact: Approved products include Jelmyto (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial cancer (UTUC) and Zusduri (mitomycin for intravesical solution) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) in adults.
Interpretation: The RTGel platform aims to improve local therapy efficacy by enabling longer tissue exposure to medications, potentially reducing the need for repeated surgical interventions like TURBT.
Uncertainty: Long-term commercial success depends on pipeline advancement (e.g., UGN-103/104 in Phase 3) and market adoption amid evolving treatment landscapes.
Data Limitation: News is based on company press releases and secondary reporting as of early August 2026; full Q2 earnings details available via IR site. Forward-looking statements involve uncertainties in regulatory approvals and commercialization.
Note: Current stock price is not displayed per guidelines. Performance metrics reflect historical trailing returns (as of early August 2026 data points).
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $140.49M | Primarily from U.S. sales of Jelmyto and Zusduri |
| Net Income (TTM) | -$133.22M | Net loss; Profit Margin -94.83% |
| EPS (TTM, diluted) | -$2.74 | Consistent with pre-profitability biotech phase |
| Total Cash (most recent quarter) | $140.27M | Supports operations and pipeline |
| Return on Assets (TTM) | -26.98% | Reflects ongoing R&D investments |
| Quarter | Total Revenue | ZUSDURI Sales | JELMYTO Sales | Net Loss |
|---|---|---|---|---|
| Q2 2026 | Not fully detailed | $50.4M (+73% QoQ) | Not specified | Not specified |
| Q1 2026 | $51.0M | $29.2M | $21.7M (+7% YoY) | $23.6M |
Interpretation: Strong Zusduri growth signals successful commercial execution for recurrent LG-IR-NMIBC; overall revenue ramp supports path toward potential profitability, though high R&D spend drives losses.
Data Limitation/Assumption: Financial figures are TTM or specific quarterly reports as of mid-2026; exact Q2 2026 totals and full balance sheet details should be verified in SEC filings or latest 10-Q. Biotech financials often assume continued funding needs.
Fact: Consensus appears strongly positive ("Strong Buy" leaning), with average 1-year price target around $44.75 (range typically $35–$50 based on recent reports).
Fact: Operates in the competitive NMIBC/urothelial cancer space with both established treatments (e.g., BCG immunotherapy, standard chemotherapy) and emerging therapies.
| Competitor / Therapy | Focus / Notes | Comparison to URGN |
|---|---|---|
| CG Oncology (CG0070) | Oncolytic virus for NMIBC | Similar intravesical approach; direct pipeline competitor |
| ImmunityBio (e.g., N-803) | IL-15 superagonist + BCG | Immunotherapy focus vs. URGN's chemoablative hydrogel |
| Johnson & Johnson (TAR-200 / TAR-210) | Intravesical delivery systems | Novel delivery competing with RTGel platform |
| Pfizer / Merck (Keytruda, etc.) | PD-1/PD-L1 inhibitors for BCG-unresponsive | Systemic vs. local therapy; different mechanism |
| enGene, Theralase, Protara | Various NMIBC candidates | Emerging players in chemo/gene/viral therapies |
Interpretation: URGN differentiates via sustained-release hydrogel for localized, prolonged exposure; competition could pressure market share but also validates the large unmet need.
Data Limitation: Competitor list is illustrative based on public NMIBC pipeline reports; exact market shares and direct head-to-head data are limited. Full landscape requires clinical trial databases and market research.